Effects of Terbutaline combined with Budesonide in treatment of patients with acute exacerbation of chronic obstructive pulmonary disease
Objective:To observe effects of Terbutaline combined with Budesonide in treatment of patients with acute exacerbation of chronic obstructive pulmonary disease(AECOPD).Methods:The clinical data of 80 patients with AECOPD admitted to the hospital from January 2020 to January 2023 were retrospectively analyzed.According to different treatment methods,they were divided into control group and study group,40 cases in each group.The control group was treated with Budesonide aerosol therapy,while the study group was treated with Terbutaline aerosol therapy on the basis of that of the control group.The clinical efficacy,the lung function indexes[forced vital capacity(FVC),forced expiratory volume in one second(FEV1),FEV1/FVC]levels,the inflammatory factors[C-reactive protein(CRP),interleukin-6(IL-6),procalcitonin(PCT)]levels,the clinical symptoms[cough and sputum assessment questionnaire(CASA-Q),the modified dyspnea index(mMRC)]score before and after the treatment,and the incidence of complications were compared between the two groups.Results:The total effective rate of treatment in the study group was 97.50%(39/40),which was higher than 80.00%(32/40)in the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of FEV1,FVC and FEV1/FVC in the two groups were higher than those before the treatment,those in the study group were higher than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of CRP,IL-6 and PCT in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the CASA-Q scores of the two groups were higher than those before the treatment,and that in the study group was higher than that in the control group;the mMRC scores of the two groups were lower than those before the treatment,and that in the study group was lower than that in the control group;and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Terbutaline combined with Budesonide in the treatment of the AECOPD patients can improve the clinical efficacy and the lung function,and reduce the body's inflammatory response and the clinical symptoms.Moreover,it is superior to single Budesonide treatment.
NETL
NSTL
万方数据
维普
